To our knowledge, several clinical trials (NCT02714010 and NCT02338011) are in progress and will compare the efficacy of upfront EGFR TKI vs. WBRT in EGFR-mutated NSCLC patients with newly diagnosed BMs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.